Company Description
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.
The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB.
It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210.
The company is headquartered in Princeton, New Jersey.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Pankaj Mohan |
Contact Details
Address: 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 United States | |
| Phone | 609 375 2227 |
| Website | sonnetbio.com |
Stock Details
| Ticker Symbol | SONN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001106838 |
| CUSIP Number | 83548R105 |
| ISIN Number | US83548R3030 |
| Employer ID | 52-2102141 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pankaj Mohan Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Dr. John K. Cini Ph.D. | Chief Scientific Officer and Co-Founder |
| Jay Cross | Chief Financial Officer |
| Donald J. Griffith CPA, CPA | Financial Controller and Director |
| Dr. Gael Hedou Ph.D. | Chief Operating Officer |
| Susan Dexter | Chief Technical Officer |
| Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer |
| Manuel Dafonseca | Head of Clinical Operations |
| Dr. Stephen J. McAndrew Ph.D. | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 19, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 10-Q | Quarterly Report |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 31, 2025 | EFFECT | Notice of Effectiveness |
| Jan 31, 2025 | EFFECT | Notice of Effectiveness |
| Jan 31, 2025 | 424B3 | Prospectus |
| Jan 31, 2025 | 424B3 | Prospectus |
| Jan 30, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 30, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 28, 2025 | 8-K | Current Report |